Recent News

• 04.25.2025 - BTX User Spotlight: Utilizing the Gemini X2 to introduce specific genetic material or modulators into neuronal cells
• 04.15.2025 - What the FDA’s Phase-Out of Animal Models in mAbs Studies Means for Drug Discovery Labs
• 04.14.2025 - Standing with Researchers in Uncertain Times: Exploring Alternative Funding Paths
• 04.11.2025 - CoaU27903NC
• 04.11.2025 - CoaU27906NC
• 04.11.2025 - CoaW27915
• 04.11.2025 - CoaU27909NC
• 04.11.2025 - CoaW27914
• 04.10.2025 - Harvard Bioscience Announces CFO Transition
• 04.10.2025 - Harvard Bioscience Announces CFO Transition

Recent Filings

• 04.22.2025 - ARS Annual Report to Security Holders
• 04.21.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.21.2025 - DEF 14A Other definitive proxy statements
• 04.16.2025 - 8-K Current report
• 04.10.2025 - 8-K Current report
• 04.10.2025 - EX-99.1 EX-99.1
• 04.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors